sorafenib has been researched along with neurotensin in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (neurotensin) | Trials (neurotensin) | Recent Studies (post-2010) (neurotensin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 4,054 | 45 | 544 |
| Protein | Taxonomy | sorafenib (IC50) | neurotensin (IC50) |
|---|---|---|---|
| Neurotensin receptor type 1 | Homo sapiens (human) | 0.0013 | |
| Neurotensin receptor type 2 | Rattus norvegicus (Norway rat) | 0.0582 | |
| Sortilin | Homo sapiens (human) | 0.36 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forgez, P; Galmiche, A; Liu, J; Paradis, V; Segal-Bendirdjian, E; Stadler, N; Wendum, D; Wu, Z | 1 |
1 other study(ies) available for sorafenib and neurotensin
| Article | Year |
|---|---|
Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Neurotensin; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transfection | 2017 |